Gemcitabine, Cisplatin, Dexamethasone, Pegaspargase and Methotrexate (GDPML) followed by Methotrexate, Cytarabine (MA) In Patients with Newly Diagnosed Aggressive T Cell Lymphoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-12002055

Enrollment

Unknown

Registered

2012-03-30

Start date

2012-02-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggressive T Cell Lymphoma

Interventions

1:Gemcitabine, Cisplatin, Dexamethasone, Pegaspargase and Methotrexate (GDPML) followed by Methotrexate, Cytarabine (MA)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of aggressive T cell lymphoma by histopathological and immunochemistry based on WHO 2008; 2. Age:18-70; 3. Eastern Cooperative Oncology Group (ECOG) status 0-2 and no chemotherapy contraindications; 4. Estimated survival time > 3 months; 5. All patients have to sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients combined with any unstable systemic diseases; 3. Hypersensitiveness to any kind of trial regime; 4. Histopathological diagnosis as followed: T lymphoblastic lymphoma,Lymphoma cells in bone marrow>=25%, Skin T cell lymphoma, ALK(+)anaplastic large cell lymphoma, Nasal Natural Killer/T Cell lymphoma stage I(nasal).

Design outcomes

Primary

Measure	Time frame
Overall Response Rate;Time to progress (TTP);	—

Secondary

Measure	Time frame
Grade 3/4 toxicities;overall survival rate;	—

Contacts

Public ContactDaobin Zhou

daobinzhou@yahoo.com+86 13901113623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 5, 2026